Trial Profile
A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Daporinad (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Valerio Therapeutics
- 08 Nov 2012 Actual end date Mar 2009 added as reported by ClinicalTrials.gov.
- 12 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Dec 2008 Updated results were presented in a TopoTarget media release.